# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/522,134	08/29/2005	Steven Jones	85084-402	3937
	7590 02/04/2008		EXAMINER	
Ade & Company 1700-360 Main Street			HURT, SHARON L	
Winnipeg Manitoba, R3C	. 373		ART UNIT	PAPER NUMBER
CANADA			1648	
			MAIL DATE	DELIVERY MODE
		•	02/04/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•		Application No.	Applicant(s)			
			JONES ET AL.			
Office Action Summary		10/522,134				
	Office Action Guilliary	Examiner	Art Unit			
	The MAILING DATE of this communication and	Sharon Hurt	1648			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAISIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It period for reply is specified above, the maximum statutory period or reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing end patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti will apply and will expire SIX (6) MONTHS fron . cause the application to become ABANDON	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
•	Responsive to communication(s) filed on <u>23 November 2007</u> .					
,	This action is <b>FINAL</b> . 2b) This action is non-final.					
3)[	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
5)□ 6)⊠ 7)□	Claim(s) <u>1-3,5,13-15,17,19-23,25 and 27-31</u> is 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) <u>1-3,5,13-15,17,19-23,25 and 27-31</u> is Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or	wn from consideration.				
Applicat	ion Papers					
10)	The specification is objected to by the Examine The drawing(s) filed onis/ are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. So tion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority	under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachmei	nt(s) ce of References Cited (PTO-892)	· 4) 🔲 Interview Summa				
2)  Noti 3)  Info	ce of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	Paper No(s)/Mail				

10/522,134 Art Unit: 1648

#### **DETAILED ACTION**

#### Status of the Claims

Claims 1-3, 5, 13-15, 17, 19-23, 25 and 27-31 are pending and under examination. Claims 4, 6-12, 16, 18, 24 and 26 have been cancelled.

### Response to Arguments

The rejection of claims 1-3, 5 and 30-31 under 35 U.S.C. 102(b) as being anticipated by **Ito et al.** (Journal of Virology, October 1999, Vol. 73, No. 10, pages 8907-8912) **is withdrawn**. Applicant's arguments, filed November 23, 2007, with respect to Ito et al. have been fully considered and are persuasive.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The rejection of claims 1-3, 5, 13-15, 17, 19-23, 25 and 27-31 under 35 U.S.C. 103(a) as being unpatentable over Ito et al. as applied to claims 1-3, 5 and 30-31 above, and further in view of Kahn et al. (Journal of Virology, Nov. 2001, Vol. 75, No. 22, pages 11079-11087) is maintained.

The claimed invention is of record. The teachings of Ito et al. (hereinafter Ito) and Kahn et al. (hereinafter Kahn) are described in the previous office action.

10/522,134 Art Unit: 1648

# Response to Arguments

Applicant's arguments filed November 23, 2007 have been fully considered but they are not persuasive. Applicant argues "Ito does not teach inserting a VHF glycoprotein into the VSV so that the VHF glycoprotein replaces VSV G". Kahn teaches a recombinant VSV expressing foreign proteins. Kahn teaches the RSV G replaced the VSV G (glycoprotein) in the viral genome and particle.

Applicant also argues "Ito does not teach 'a recombinant VSV expressing Ebola glycoprotein wherein the mutation reduced the infectivity of the VSVΔG by the incorporation of the Ebola virus glycoprotein into recombinant VSV particles'." Ito teaches a recombinant VSV wherein the Ebola virus glycoprotein was incorporated into recombinant VS particles. The combination of references teaches the instant claimed invention.

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharon Hurt whose telephone number is 571-272-3334. The examiner can normally be reached on M-F 8:00 - 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

**Sharon Hurt** 

January 31, 2008

/Bruce Campell/ Supervisory Patent Examiner Art Unit 1648